Treatment of HCV-related liver disease in the dialysis population: a novel challenge for clinical nephrologists.
Fabrizi
F
F
Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy. ponticel@polic.cilea.it
Lunghi
G
G
Martin
P
P
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008107:Liver Diseases / Q000188:drug therapy* / Q000821:virology*; D011994:Recombinant Proteins; D006435:Renal Dialysis
D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins